Across TCGA pan-cancer cohorts, SEC14L6 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SEC14L6 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher SEC14L6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SEC14L6 expression acts as an unfavorable survival marker.
SARC are the cancer types where SEC14L6 Mutation most reproducibly stratifies survival.